Curriculum Vitaes

Naoki Yamamoto

  (山本 直樹)

Profile Information

Affiliation
Professor, Center for Society-Academia Collaboration, Research Promotion Headquarters, Fujita Health University
(Concurrent)Professor, International Center for Cell and Gene Therapy, Research Promotion Headquarters
(Concurrent)Professor, Graduate School of Medical Sciences
Degree
医学博士(藤田保健衛生大学)

Contact information
naokiyfujita-hu.ac.jp
Researcher number
00267957
J-GLOBAL ID
200901054071171303
researchmap Member ID
6000005815

External link

Education

 1

Papers

 207
  • Kei Ichikawa, Seiji Tokiwa, Yoshiki Tanaka, Hiroto Toda, Yukihito Kato, Yukihiro Sakai, Kazuo Ichikawa, Naoki Yamamoto
    Journal of Clinical Medicine, Sep, 2025  
  • Kei Ichikawa, Yoshiki Tanaka, Rie Horai, Yu Kato, Kazuo Ichikawa, Naoki Yamamoto
    Medicina, 61(8) 1384-1384, Jul 30, 2025  Peer-reviewedLast author
    Background and Objectives: Posterior chamber phakic implantable contact lenses (Phakic-ICL) are widely used for refractive correction due to their efficacy and safety, including minimal corneal endothelial cell loss. The Collamer-based EVO+ Visian implantable contact lens (ICL), manufactured from Collamer, which is a blend of collagen and hydroxyethyl methacrylate (HEMA), has demonstrated excellent long-term biocompatibility and optical clarity. Recently, hydrophilic acrylic Phakic-ICLs, such as the Implantable Phakic Contact Lens (IPCL), have been introduced. This study investigated the material differences among Phakic-ICLs and their interaction with fibronectin (FN), which has been reported to adhere to intraocular lens (IOL) surfaces following implantation. The aim was to compare Collamer, IPCL, and LENTIS lenses (used as control) in terms of FN distribution and cell adhesion using a small number of explanted Phakic-ICLs. Materials and Methods: Three lens types were analyzed: a Collamer Phakic-ICL (EVO+ Visian ICL), a hydrophilic acrylic IPCL, and a hydrophilic acrylic phakic-IOL (LENTIS). FN distribution and cell adhesion were evaluated across different regions of each lens. An in vitro FN-coating experiment was conducted to assess its effect on cell adhesion. Results: All lenses demonstrated minimal FN deposition and cellular adhesion in the central optical zone. A thin FN film was observed on the haptics of Collamer lenses, while FN adhesion was weaker or absent on IPCL and LENTIS surfaces. Following FN coating, Collamer lenses supported more uniform FN film formation; however, this did not significantly enhance cell adhesion. Conclusions: Collamer, which contains collagen, promotes FN film formation. Although FN film formation was enhanced, the low cell-adhesive properties of HEMA resulted in minimal cell adhesion even with FN presence. This characteristic may contribute to the long-term transparency and biocompatibility observed clinically. In contrast, hydrophilic acrylic materials used in IPCL and LENTIS demonstrated limited FN interaction. These material differences may influence extracellular matrix protein deposition and biocompatibility in clinical settings, warranting further investigation.
  • Yu Kato, Takeshi Inaba, Koudai Shinke, Noriko Hiramatsu, Tetsuhiro Horie, Takuya Sakamoto, Yuko Hata, Eiji Sugihara, Tetsuya Takimoto, Noriaki Nagai, Yasuhito Ishigaki, Hajime Kojima, Osamu Nagano, Naoki Yamamoto, Hideyuki Saya
    Cells, 14(3) 215-215, Feb 2, 2025  Peer-reviewedCorresponding author
    Developmental toxicity testing is essential to identify substances that may harm embryonic development. This study aimed to establish a protocol for evaluating developmental toxicity using human induced pluripotent stem cells (iPSCs) by analyzing cellular activity and gene expression changes. Two ICH S5(R3) positive substances, valproic acid (VPA), which is a substance previously detected as positive by other test methods, and thalidomide (Thalido), were examined during early trichoderm differentiation without fetal bovine serum. RNA-seq analysis identified seven candidate genes, including TP63, associated with altered expression following exposure to VPA or Thalido. These genes were implicated in pathways related to tissue development, cell growth, and molecular interactions. While the assay effectively detected VPA and Thalido, its limitations include testing only soluble substances and focusing on early differentiation stages. Nevertheless, the protocol demonstrates potential for the classification and evaluation of emerging modality drugs based on physical properties such as solubility, polarity, and pH. Integration with AI analysis may enhance its capacity to uncover genetic variations and evaluate previously uncharacterized substances. This study provides a foundation for alternative developmental toxicity testing methods, with further refinements in the culture method expected to improve accuracy and applicability in regulatory toxicology.
  • Hiroko Otake, Tetsushi Yamamoto, Naoki YAMAMOTO, Yosuke Nakazawa, Yoshiki Miyata, Atsushi Taga, HIROSHI SASAKI, Noriaki Nagai
    Medicina, Feb, 2025  
  • Takuya Sakamoto, Atsushi Fuku, Tetsuhiro Horie, Hironori Kitajima, Yuka Nakamura, Ikuhiro Tanida, Hiroshi Sunami, Hiroaki Hirata, Yoshiyuki Tachi, Yasuo Iida, Sohsuke Yamada, Naoki Yamamoto, Yusuke Shimizu, Yasuhito Ishigaki, Toru Ichiseki, Ayumi Kaneuji, Satoshi Osawa, Norio Kawahara
    Regenerative Therapy, 27 408-418, Dec, 2024  

Misc.

 56

Books and Other Publications

 10
  • 山本 直樹 (Role: Contributor, 第2章 動物実験代替法における評価モデル 、第3節 不死化ヒト角膜上皮細胞株を用いた眼刺激性試験代替法)
    株式会社 技術情報協会, Jun, 2018
  • 山本 直樹 (Role: Joint author, 細胞培養基盤技術)
    株式会社 じほう, Jun, 2013
  • 山本 直樹 (Role: Contributor, フルオレセイン漏出試験法(Fluorescein leakage test method; FL試験法))
    株式会社 シーエムシー出版, Jun, 2013
  • 山本 直樹 (Role: Contributor, アトピー白内障 -その発症に関与する要因とメカニズム-)
    学際企画株式会社, Jun, 2011
  • 山本 直樹 (Role: Contributor, 子どもに多い目の病気 “感染予防の必要性の有無と指導の実際")
    健学社, Oct, 2008

Presentations

 51

Teaching Experience

 7

Works

 1

Research Projects

 23

Industrial Property Rights

 4

Other

 3
  • 市販のリプログラミングベクターを用いて、ヒト末梢血単球由来iPS細胞を作製することに成功した。研究成果は、以下のジャーナルで報告している。Isogai S, Yamamoto N et al., Cell Reprogram 20(6), 347-355, 2018. Hiramatsu N, Yamamoto N et al., Med Mol Morphol 53(2), 63-72, 2020. *本研究シーズに関する産学共同研究の問い合わせは藤田医科大学産学連携推進センター(fuji-san@fujita-hu.ac.jp)まで
  • ヒト虹彩由来iPS細胞の作製に成功した。研究成果は、以下のジャーナルで報告している。Yamamoto N et al., Cells 10(4), 743, 2021. *本研究シーズに関する産学共同研究の問い合わせは藤田医科大学産学連携推進センター(fuji-san@fujita-hu.ac.jp)まで
  • 臓器・組織を迅速に固定できる固定液を発明。日本で特許を取得(特許3723204 難浸透性組織迅速固定液)。本特許の技術の一部を利用した商品(組織用迅速固定液 スーパーフィックス KY-500, クラボウ)が販売されている。他にも、本特許技術を用いた無ホルマリン固定液を開発中。 *本研究シーズに関する産学共同研究の問い合わせは藤田医科大学産学連携推進センター(fuji-san@fujita-hu.ac.jp)まで